Posts

White House Launches TrumpRx.gov as Key Pillar of Most Favored Nation Drug Pricing Deals

President Trump unveiled TrumpRx.gov on February 5, 2026, at a White House event, offering discounts on 40 popular branded drugs from manufacturers like Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, and EMD Serono. 1 2 3 The platform uses Most Favored Nation (MFN) pricing to align U.S. prices with the lowest in other developed nations, following executive orders and deals announced since May 2025. 1 2 Examples of discounts include Wegovy pill from $1,349 to $149/month, Ozempic to $350 or $199, insulin Lispro to $25/month, and inhalers like Bevespi Aerosphere from $458 to $51. 1 2 The site provides coupons or direct channels for cash-paying patients, bypassing insurance, with more drugs to be added soon. 2 3 4 Trump described it as one of the most transformative health care initiatives, part of his Great Healthcare Plan calling for congressional codification. 1 2 Sources: 1. https://abcnews.go.com/Politics/trump-unveil-trumprx-website-americans-buy-lower-priced/story?id=1298...

Roivant Spinout Priovant Advances Brepocitinib to Phase 3 with Landmark Phase 2 Data in Cutaneous Sarcoidosis

Atropos Health Announces Key New Hires: Sylvia Isler as CTO and Drew Turitz as CFO

Hims Launches Compounded Semaglutide Pill Challenging Novo's Oral Wegovy Amid Legal Threats

Polaryx Therapeutics Welcomes New Members to Board of Directors

Veradermics Successfully Completes Upsized $256M IPO for Oral Hair Loss Treatment

Hims & Hers Partners with Grail to Offer Galleri Multi-Cancer Early Detection Test Amid FDA Review

Amgen Rejects FDA Request to Withdraw Rare Disease Drug Tavneos

Clinical Trials Going Global with China as Key Beneficiary

AstraZeneca Receives FDA Complete Response Letter for Subcutaneous Saphnelo in Lupus

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Eli Lilly Beats Sales Forecasts and Targets Major 2026 Growth, Outpacing Novo Nordisk

Valo Health Appoints Karin Conde-Knape as Chief Scientific Officer